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ABSTRACT
Dengue is a viral disease caused by an RNA virus of the genus Flavivirus, family Flaviviridae, occurring as
four serotypes (DEN-1, -2, -3, -4). It is transmitted to humans by the Aedes mosquitoes, mainly A. aegypti.
The occurrence of dengue is strictly related with their preferred breeding areas. Dengue endemic regions
are inhabited by some 2.5 billion people. 50–100 million cases of dengue fever and up to 1 million cases
of dengue haemorrhagic fever are noted worldwide in more than 100 countries every year. The aim of the
reported examinations was to diagnose dengue virus infections in returning travellers. In the years 2006–
–2009 serological tests were performed in 753 persons. In the diagnostics we used ELISA to find IgM
and/or IgG class of antibodies against dengue virus, rapid immunochromatographic (cassette) test, NS1
viral antigen detection by ELISA, and virus RNA detection by RT-PCR method. IgM or IgG class antibodies,
and both classes simultaneously, were detected in 19.8% of the examined cases. The greatest number of
infections came from India and the Far East, next from South and Central America, and the smallest
number from Africa. Sixteen patients with diagnosed dengue, including three cases of dengue haemor-
rhagic fever, were hospitalized.

INTRODUCTION
Dengue fever is one of the most widespread imported
febrile diseases in European travellers returning from tropi-
cal regions [1]. It is caused by four RNA virus serotypes (DEN-
1, -2, -3, and -4) of the genus Flavivirus, family Flaviviridae,
“related” with viruses of West Nile fever, yellow fever, and
Japanese encephalitis. The disease is transmitted by mos-
quitoes of the Aedes family, mainly A. aegypti, and less fre-
quently by A. albopticus and A. polynesiensis [2]. The pre-
valence of dengue is strictly connected with the feeding
areas of these mosquitoes. Aedes spp. mosquitoes can
reproduce and survive only in the presence of water (natu-
ral and artificial fresh water containers) within specific tem-
perature ranges. Frosts and freezing of water cause da-
mage to breeding sites, thus restricting the spread of the
di-sease to moderate climate zones.
More than 2.5 billion people, i.e. about 40% of the
world’s population, inhabit dengue endemic areas in South-
East and South Asia, the American continents, Central Afri-
ca, and  the islands of West and East Pacific [2, 3].
Each year, from 50 to 100 million dengue incidents are
documented as classic dengue fever (CDF) and up to 1 mil-
lion cases of dengue haemorrhagic fever (DHF). The num-
ber of notified dengue incidents has increased several times
over the last 50 years due to urbanization of tropical re-
gions, global warming, and the possibility of rapid displace-
ment of persons in the viraemic period and those infected
with mosquito viruses, e.g. by air transportation facilities.
The geographical range of dengue incidence is also expan-
ding. While in 2001 dengue was registered in 69 countries,
in 2008 it occurred in over 100 countries worldwide. Before
1970, DHF outbreaks were noted in 9 countries only. By
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1995 this number had increased more than fourfold [4, 5].
In view of the mild course of many dengue infections, the
real number of dengue cases may be 5–10-fold higher.
Every few years, an epidemic increase in dengue incidence
is observed [6].
The sick people in the viraemic period, i.e. from the 1st
to the 4th day from the onset of the disease, constitute the
reservoir of the dengue. The incubation period amounts to
4–8 days. Past disease guarantees lifelong permanent im-
munity, specific for a given virus serotype [7, 8].
Each year there is an increasing number of Polish trav-
ellers to the tropics, i.e. to dengue fever prevalence. The
number of imported dengue cases is increasing in Poland.
Until 2005, no diagnostic tests were performed in Po-
land regarding dengue virus infection. Therefore, in avail-
able literature there are no epidemiological data on impor-
ted dengue in Poland, the number of people with past infec-
tion or antibodies against the dengue virus after a stay in
an endemic region, or on examination results allowing the
assessment of infection risk during travel.
The aim of the investigation was to evaluate the frequen-
cy of occurrence of antibodies against dengue virus in per-
sons returning from dengue-endemic areas, to assess the
usefulness of other tests (detection of NS1 virus antigen by
ELISA and of viral RNA by RT-PCR) in diagnosing dengue
fever, and to evaluate the risk of dengue virus infection in
Polish travellers to the tropics.
MATERIAL AND METHODS
The study group consisted of 753 patients (320 women
aged 20–71 years and 433 men aged 19–77 years) of the
Clinic of Tropical and Parasitic Diseases of the Medical Uni-
versity of Gdańsk and the Outpatient Clinic of Infectious,
Tropical, and Parasitic Diseases of the University Centre for
Maritime and Tropical Medicine in Gdynia, who were sub-
jected to routine examinations after a stay in the tropics or
were hospitalized in the Clinic for morbid symptoms in the
years 2006–2009.
In the diagnostics of the infection, serological tests were
performed by ELISA to detect IgM and IgG class antibodies
against dengue virus (IBL International and Panbio). In the
diagnostics of the infection, serological test were performed
by ELISA to detect IgM and IgG class antibodies against
dengue virus (IBL International and Panbio). When serolo-
gical tests results were doubtful as to the specificity of anti-
bodies detected (e.g. isolated presence of IgM class low-
titre antibodies), the tests were repeated after four weeks
[9]. This concerned 62 person. In febrile patients, rapid im-
munochromatographic (cassette) test for IgM/IgG (Panbio),
detection of NS1 virus antigen presence by ELISA (Panbio),
and viral RNA examination by RT-PCR were performed. Com-
mercial tests were performed according to the manufactu-
rer's instructions. Reverse transcription-polymerase chain
reaction (RT-PCR) was performed using QIAGEN OneStep RT-
-PCR Kit (Qiagen) [10]. Sequences obtained from two posi-
tive patients showed 99.7% homology to the sequence from
cosmopolitan Brunei DEN-2 virus strain [11] deposited in
Gen Bank database (accession no EU179858).
RESULTS
The presence of IgG, IgG+IgM, and IgM class antibodies
against dengue virus was found in 191 (23.37%) of the 753
persons examined. In 62 persons with isolated presence of
low-titre IgM class antibodies, the tests were repeated after
4 weeks. No antibodies were detected in 42 cases, whereas in
20 the titre of IgM class antibodies against dengue virus was
higher. IgG class antibodies also appeared. Thus, after verifi-
cation and rejection of results regarded in 42 persons as
unspecific in the first examination, dengue virus infection was
diagnosed in 149 travellers to the tropics (19.8% of the study
group). In 20 persons IgM class early antibodies were detect-
ed, and in 45 both IgM and IgG class antibodies were detect-
ed. In 84 cases the tests revealed only IgG class late antibod-
ies. NS1 antigen presence was found in one patient for 8 fe-
brile and 41 non-febrile patients examined. The results are
summarized in Table 1.
The group of 149 persons in which antibodies were found
was also analyzed with regard to the place and length of
stay in the tropics (period of exposure to possible dengue
virus infection), and the purpose of the journey. In 81 ca-
ses, epidemiological data in medical documentation indica-
ted that the exposure to infection probably occurred in the
following regions:
— Far East (Thailand, Vietnam, Laos, Cambodia, Korea, Chi-
na) — 15 cases;
— South Asia (India, Afghanistan, Pakistan) — 16 cases;
— South and Central America (Brazil, Argentina, Bolivia,
Peru, Cuba, Dominican Republic, Belize, Mexico) — 26
cases;
Table 1. Types of tests performed and their results
Type of test Number and percentage
of positive results
Antibodies (ELISA):
IgM 20 (13.4%)
IgM+IgG 45 (30.2%)
IgG 84 (56.4%)
NS1 antigen in the blood 0/49 examinations
Virus RNA in the blood 2/14 examinations
Rapid immunochromatographic test 12 IgM+
IgM/IgG (cassette) 2 IgM+IgG+
16 negative results
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— Central Africa (Angola, Cameroon, Nigeria, Ghana, Con-
go, Zaire, Tanzania, Kenya, Central African Republic,
Zambia, Sudan) — 21 cases, Morocco — 3 cases.
The remaining 68 persons stayed in dengue-endemic
areas, but the place of their stay was not established pre-
cisely.
The length of stay in dengue-endemic regions varied
markedly: from one to several weeks for tourists, several
months to a few years for persons working in the tropics,
and from several months to as long as 33 years for mission-
aries.
The purposes of travel included contract and mission
work, tourism (including visits to working relatives), and prac-
tising some kind of sport (rock and mountain climbing, par-
ticipation in rallies, coral reef diving, cave exploration, etc.).
Among 149 patients with detected antibodies against den-
gue virus, there were 39 tourists and 85 persons working in
dengue-endemic regions. In 25 cases the type of occupa-
tion taken up was not established. The cross-sectional anal-
ysis of occupations is given in Table 2.
The study group included 16 febrile patients, for whom
serological, and in two cases molecular, tests confirmed the
diagnosis of dengue. These patients were hospitalized in
the Clinic of Tropical and Parasitic Diseases. As regards the
occupation, this group consisted of five tourists, five regu-
lar soldiers, four representatives of other professions, and
two missionaries. Thus, people staying more than a few
weeks in the tropics prevailed. The length of hospitalization
of patients with dengue varied from 3 to 17 days. Six per-
sons stayed in the Clinic more than ten days, three of them
with diagnosed dengue haemorrhagic fever [12].
DISCUSSION
Results of serological tests performed in the University
Centre for Maritime and Tropical Medicine indicate a seri-
ous risk of dengue virus infection during stays in endemic
regions. This concerned about 1/5 of the patients exam-
ined. However, it should be emphasized that the group was
not chosen at random. The people qualified for examina-
tions reported sick of their own accord due to ailments that
might be related with their travel, or underwent compulsory
medical examination as part of routine prophylaxis with
regard to workers delegated to the tropics. It should be poin-
ted out that although dengue requires mosquitoes as vec-
tors and occurs primarily in regions of high population den-
sity where mosquito breeding sites are close to urban
districts, antibodies were detected also in three seafarers
and three marine drilling platform workers.
It is worth noting that in the group with antibodies against
dengue virus, workers and missionaries prevailed over tou-
rists: 57% vs. 26.2%. Taking into account that the risk fac-
tors for acquiring tropical diseases, including dengue, are:
the length of stay in endemic regions, wet season favouring
mass mosquito hatching, disregard of unspecific prophyla-
xis, and lack of awareness of the disease threat. Workers
staying in the tropics year-long, for several years in particu-
lar, are most exposed to infection [13, 14]. It is understan-
dable that tourists choose safer seasons, from November
until the end of February in the northern hemisphere where
the wet season lasts from August to October. In the southern
hemisphere, the high tourist season lasts from May to Au-
gust, and the wet season from February to April. Touristic
stays usually last for 1–2 weeks and more rarely 3–4 weeks.
Hence, dengue virus infection in only 26.2% of tourists is
not surprising.
As known from WHO publications, the highest dengue
virus threat exists in South-East Asia and on the Indian sub-
continent, where the greatest dengue incidence is recor-
ded, followed by South and Central America, and Africa, with
the lowest number of cases in the Oceania region [4]. Our
investigations have demonstrated that the patients exa-
mined were infected with dengue virus in Asia, South and
Central America, and Africa in almost equal proportions [31,
26 and 24, respectively]. There were no travellers to the
Oceania region in this group. Considerably different results
of epidemiological examinations were reported by authors
from Austria [15]. Among 93 patients hospitalized with
a diagnosis of dengue in Vienna Municipal Hospital in the
Table 2. The occupation of the patients
Occupation Number Occupation Number
of people examined of people examined
Missionaries 29 Travellers and journalists 5
Seafarers 3 Sportsmen 3
Regular soldiers 11 Bartenders and waiters 2
Surface miners 7 Participants of charitable missions 4
Workers of natural gas mining industry 3 Physicians and nurses 3
Marine drilling platform workers 3 Agricultural pilots 2
Engineers 4 Stewardesses 1
Geodesists 4 Artists 1
Not established 25
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years 1990–2005, 56% were infected with dengue virus in
South-East Asia, 18% in India, 10% in Africa, and 3% in Oce-
ania. In the years 2001–2004, 366 patients were exa-
mined in the USA with a suspicion of imported dengue, which
was diagnosed in 77 persons. According to history data, for
30% of patients the destination and probable place of in-
fection were Caribbean Islands, Pacific Islands for 21%, Asia
for 17%, Central America for 15%, South America for 15%,
and Africa for 2% [16, 17]. The above data indicate that
depending on the country, there are different preferences
as to the destination of the journey. In our investigations,
a markedly higher number of infections contracted most like-
ly in Africa was noted compared to that usually reported.
This is probably due to the considerable proportion of mis-
sionaries, working mainly in Africa, in our study group.
In the diagnostics of dengue virus infection, serological
methods (determination of NS1 antigen, IgG, and IgM class
antibodies) and in some cases virus RNA identification by
RT-PCR were employed. According to the test producer’s in-
formation, it should be taken into account that the isolated
small increase in IgM class antibody level may result from
an unspecific reaction, for example, because of the cross-
reactions with other flaviviridae. In such cases the test should
be repeated for verification after a week or more. It was found
that as many as 42 tests from 62 verified were regarded as
false-positive. This may be the reason for dengue “overdia-
gnosing” by inexperienced physicians [18]. There is a possi-
bility of cross-reactivity of antibodies to a yellow fever virus
among Polish travellers going to South and Latin America,
and Africa, who were vaccinated. There is no vaccine for the
West Nile Virus fever; in addition, the morbidity caused by
this fever is not reported in Poland, with just one exception
described in 2007. Vaccination for Japanese encephalitis is
not commonly available in Poland. Only small groups of wor-
kers going to the endemic regions of this disease are occa-
sionally vaccinated. Therefore, cross-reactions between the
two viruses mentioned above can be considered only among
travellers frequently visiting the tropics. Unfortunately, these
data were not available in medical records.
Rapid IgM/IgG cassette proved very useful in diagno-
sing dengue in the early infection stage in febrile patients
because the result of the test is obtained after just 15 mi-
nutes, allowing differentiation between the primary and se-
condary infection. It is also quite specific since it is compati-
ble in over 90% of cases, with results obtained by ELISA in
classic determination of IgG and IgM antibodies, and it is
inexpensive.
Thirty tests were performed, in 14 cases yielding a pos-
itive result for IgM antibodies, corresponding to the early
stage of dengue virus infection. In two cases IgM+IgG class
antibodies were also found, which suggests infection with a
second or successive dengue virus serotype. Such a result
is of prognostic significance since dengue haemorrhagic
fever does not occur in persons infected for the first time. It
may develop upon subsequent infection, probably with vi-
rus serotype 2. RT-PCR method allows identification of the
virus type responsible for the disease.
Over 49 serological tests were performed to find NS1
antigen of dengue virus in the blood of febrile patients re-
turning from the tropics. No positive result was obtained,
even in patients with diagnosed dengue. Since the virus
antigen remains in blood until the 4th –8th day from the on-
set of the disease, and the return from the dengue-ende-
mic region usually lasts 1–2 days, the antigen frequently
becomes indeterminable by diagnostic tests. The usefulness
of this method for Polish tourists diagnosed in Poland seems
doubtful. Virus RNA determination in the blood by RT-PCR,
allowing RNA detection after 4–6 days from the infection, is
more useful and sensitive. Nonetheless, it is more expen-
sive, less readily available, and is not performed as a mat-
ter of urgency.
Dengue is rarely diagnosed in Poland, although 50–
–100 million cases are reported worldwide, and the real
number is much higher. In the majority of cases the course
of dengue is mild and almost symptomless, resulting in
disregard of the disease and abandonment of diagnostics.
However, haemorrhagic fever symptoms are sometimes
observed. In view of the lack of a vaccine against dengue,
knowledge about unspecific prophylaxis is indispensable,
particularly among people sent to work in dengue-ende-
mic areas.
Despite the continual increase in the number of diag-
nosed cases of imported dengue in Poland, the experience
of Polish physicians in prevention, diagnosis, and treatment
of this disease is still insufficient. In the current epidemio-
logical situation it seems that the diagnostic methods dis-
cussed in the present paper and offered in our centre are
effective for proper dengue diagnosis.
CONCLUSIONS
1. Serological tests have demonstrated that 149 travellers
to the tropics (19.8% of 753 cases examined) might have
been infected by dengue virus.
2. Almost half (43.6%) of the persons with detected anti-
bodies showed the presence of early antibodies in blood.
3. In 16 patients (2.1% of the study group) dengue fever
was diagnosed, with dengue haemorrhagic fever in
3 cases.
4. It seems that the risk of dengue virus infection when
visiting the tropics is quite high, particularly during longer
(several months or years) stays in regions endemic for
this disease, frequently connected with work performed.
5. Travellers to the tropics should be acquainted with un-
specific prophylaxis against dengue.
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